Strategies to prevent type 2 diabetes

Hussam Abuissa, D. S H Bell, James H. O'Keefe

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

Type 2 diabetes mellitus is a public health problem of epidemic proportions and its prevalence is on the rise. The typical American born today has a one in three chance of developing type 2 diabetes. This diagnosis is associated with an adverse cardiovascular prognosis and is considered the risk equivalent of established coronary disease. Many risk factors, including the metabolic syndrome, have been implicated in its development. Even in high-risk individuals, type 2 diabetes is a preventable disease. Diet and exercise have been consistently shown to decrease the incidence of diabetes in large randomized controlled studies. Additionally, new-onset diabetes was reduced by several oral pharmacologic anti-diabetic agents including metformin, acarbose and troglitazone in randomized trials which studied patients with impaired glucose tolerance. More interestingly, multiple large prospective studies have also reported a reduction in the development of type 2 diabetes in patients treated with anti-hypertensive agents, predominantly angiotensin converting enzyme inhibitors and angiotensin receptor blockers. In this review, we will discuss some of these important trials and the speculative mechanisms whereby those medications prevent type 2 diabetes. Such observations, if proven to be true, may represent preventive strategies which can be considered in patients with pre-diabetic conditions such as the metabolic syndrome, hypertension, impaired fasting glucose, family history of diabetes, obesity, congestive heart failure or other risks for the development of type 2 diabetes.

Original languageEnglish
Pages (from-to)1107-1114
Number of pages8
JournalCurrent Medical Research and Opinion
Volume21
Issue number7
DOIs
StatePublished - Jul 2005
Externally publishedYes

Fingerprint

Type 2 Diabetes Mellitus
troglitazone
Acarbose
Glucose Intolerance
Angiotensin Receptor Antagonists
Metformin
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Coronary Disease
Fasting
Heart Failure
Public Health
Obesity
Prospective Studies
Exercise
Diet
Hypertension
Glucose
Incidence

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Strategies to prevent type 2 diabetes. / Abuissa, Hussam; Bell, D. S H; O'Keefe, James H.

In: Current Medical Research and Opinion, Vol. 21, No. 7, 07.2005, p. 1107-1114.

Research output: Contribution to journalReview article

Abuissa, Hussam ; Bell, D. S H ; O'Keefe, James H. / Strategies to prevent type 2 diabetes. In: Current Medical Research and Opinion. 2005 ; Vol. 21, No. 7. pp. 1107-1114.
@article{812360848fc7491cb5341d1560638668,
title = "Strategies to prevent type 2 diabetes",
abstract = "Type 2 diabetes mellitus is a public health problem of epidemic proportions and its prevalence is on the rise. The typical American born today has a one in three chance of developing type 2 diabetes. This diagnosis is associated with an adverse cardiovascular prognosis and is considered the risk equivalent of established coronary disease. Many risk factors, including the metabolic syndrome, have been implicated in its development. Even in high-risk individuals, type 2 diabetes is a preventable disease. Diet and exercise have been consistently shown to decrease the incidence of diabetes in large randomized controlled studies. Additionally, new-onset diabetes was reduced by several oral pharmacologic anti-diabetic agents including metformin, acarbose and troglitazone in randomized trials which studied patients with impaired glucose tolerance. More interestingly, multiple large prospective studies have also reported a reduction in the development of type 2 diabetes in patients treated with anti-hypertensive agents, predominantly angiotensin converting enzyme inhibitors and angiotensin receptor blockers. In this review, we will discuss some of these important trials and the speculative mechanisms whereby those medications prevent type 2 diabetes. Such observations, if proven to be true, may represent preventive strategies which can be considered in patients with pre-diabetic conditions such as the metabolic syndrome, hypertension, impaired fasting glucose, family history of diabetes, obesity, congestive heart failure or other risks for the development of type 2 diabetes.",
author = "Hussam Abuissa and Bell, {D. S H} and O'Keefe, {James H.}",
year = "2005",
month = "7",
doi = "10.1185/030079905X50606",
language = "English",
volume = "21",
pages = "1107--1114",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Strategies to prevent type 2 diabetes

AU - Abuissa, Hussam

AU - Bell, D. S H

AU - O'Keefe, James H.

PY - 2005/7

Y1 - 2005/7

N2 - Type 2 diabetes mellitus is a public health problem of epidemic proportions and its prevalence is on the rise. The typical American born today has a one in three chance of developing type 2 diabetes. This diagnosis is associated with an adverse cardiovascular prognosis and is considered the risk equivalent of established coronary disease. Many risk factors, including the metabolic syndrome, have been implicated in its development. Even in high-risk individuals, type 2 diabetes is a preventable disease. Diet and exercise have been consistently shown to decrease the incidence of diabetes in large randomized controlled studies. Additionally, new-onset diabetes was reduced by several oral pharmacologic anti-diabetic agents including metformin, acarbose and troglitazone in randomized trials which studied patients with impaired glucose tolerance. More interestingly, multiple large prospective studies have also reported a reduction in the development of type 2 diabetes in patients treated with anti-hypertensive agents, predominantly angiotensin converting enzyme inhibitors and angiotensin receptor blockers. In this review, we will discuss some of these important trials and the speculative mechanisms whereby those medications prevent type 2 diabetes. Such observations, if proven to be true, may represent preventive strategies which can be considered in patients with pre-diabetic conditions such as the metabolic syndrome, hypertension, impaired fasting glucose, family history of diabetes, obesity, congestive heart failure or other risks for the development of type 2 diabetes.

AB - Type 2 diabetes mellitus is a public health problem of epidemic proportions and its prevalence is on the rise. The typical American born today has a one in three chance of developing type 2 diabetes. This diagnosis is associated with an adverse cardiovascular prognosis and is considered the risk equivalent of established coronary disease. Many risk factors, including the metabolic syndrome, have been implicated in its development. Even in high-risk individuals, type 2 diabetes is a preventable disease. Diet and exercise have been consistently shown to decrease the incidence of diabetes in large randomized controlled studies. Additionally, new-onset diabetes was reduced by several oral pharmacologic anti-diabetic agents including metformin, acarbose and troglitazone in randomized trials which studied patients with impaired glucose tolerance. More interestingly, multiple large prospective studies have also reported a reduction in the development of type 2 diabetes in patients treated with anti-hypertensive agents, predominantly angiotensin converting enzyme inhibitors and angiotensin receptor blockers. In this review, we will discuss some of these important trials and the speculative mechanisms whereby those medications prevent type 2 diabetes. Such observations, if proven to be true, may represent preventive strategies which can be considered in patients with pre-diabetic conditions such as the metabolic syndrome, hypertension, impaired fasting glucose, family history of diabetes, obesity, congestive heart failure or other risks for the development of type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=22744450471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22744450471&partnerID=8YFLogxK

U2 - 10.1185/030079905X50606

DO - 10.1185/030079905X50606

M3 - Review article

C2 - 16004680

AN - SCOPUS:22744450471

VL - 21

SP - 1107

EP - 1114

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 7

ER -